Search
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in
Products: MESTİNON 60 MG KAPLI TABLET, 20 ADET, MİYASTU 180 MG UZATILMIŞ SALIMLI TABLET, 30 ADETPegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5. … [A235000,A235005] Pegcetacoplan is a pegylated C3 inhibitor that can disrupt the processes leading to both forms of hemolysis that threaten patients with PNH.
LV305
go.drugbank.com/drugs/DB17288InvestigationalLV305 is a lentiviral vector encoding NY-ESO-1 gene. LV305 is an active component of CMB305 along with [G305].[L47346]
Gepirone
go.drugbank.com/drugs/DB12184ApprovedGepirone, an azapirone, is a pharmacologic analog of [buspirone] that acts selectively on the pre- and post-synaptic 5HT<sub>1A</sub> receptors. … It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRomiplostim
go.drugbank.com/drugs/DB05332ApprovedInvestigationalEach subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. … Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor.
Products: NPLATE 250 MCG ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADET, NPLATE 500 MCG ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 1 ADETSafrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnSafrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR). … Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain
Obeticholic acid
go.drugbank.com/drugs/DB05990ApprovedInvestigationalhepatic decompensation) due to a risk of liver failure, in some cases requiring liver transplantation. … [A192786] Obeticholic acid is a farnesoid-X receptor (FXR) agonist used to treat this condition, possibly allowing for increased survival.
Canis lupus familiaris hair
go.drugbank.com/drugs/DB10867ApprovedDomestic dog hair is used in allergenic testing.
Mixtures: Animal Allergens, AP Dog Hair and Dander Canis spp, Animal Allergens, AP Dog Hair and Dander Canis sppProducts: Treatment Set TS340987Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalA safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800] … [A34604] This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities.
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index